BACH1; FANCJ; OF
The BRIP1 gene is associated with an increased risk for autosomal dominant ovarian cancer and possibly breast cancer in individuals who carry a single pathogenic BRIP1 variant (PMID: 17033622, 21964575, 26315354). Additionally, the BRIP1 gene is associated with autosomal recessive Fanconi anemia (MedGen UID: 323015).
Order this gene as a single gene test.
Invitae tests that include this gene:
The BRIP1 gene encodes a helicase that interacts with the BRCT repeats of BRCA1. The bound complex is important in the normal double-strand break repair function of BRCA1.
MedGen UID: 87542
Women who are carriers of a single pathogenic BRIP1 variant have an increased risk of breast and ovarian cancer. Evidence suggests the risk of ovarian cancer is approximately 8% (PMID: 17033622, 21964575, 26720728, 26315354) ; however, the association and risk of breast cancer is yet to be determined (PMID: 21964575, 17033622). An individual with a BRIP1 pathogenic variant will not necessarily develop cancer in their lifetime, but the risk for cancer is increased over the general population risk.
There is also evidence to suggest an association between BRIP1 and hematologic malignancies, and is therefore available as a preliminary-evidence gene gene on the Invitae Myelodysplastic Syndrome/Leukemia Panel. Preliminary-evidence genes are selected from an extensive review of the literature and expert recommendations, but the association between the gene and the specific condition has not been completely established. This uncertainty may be resolved as new information becomes available, and therefore clinicians may continue to order these preliminary-evidence genes.
The BRIP1 gene is required for the maintenance of chromosomal stability. It acts late in the Fanconi anemia pathway and is involved in the repair of DNA double-strand breaks by homologously recombining in a manner that depends on its association with BRCA1 ( UniProtKB – Q9BX63). If there is a pathogenic variant in this gene that prevents it from functioning normally, the risk of developing certain types of cancers is increased.
Hereditary predisposition to cancer due to a single pathogenic variant in the BRIP1 gene has autosomal dominant inheritance. This means that an individual with a pathogenic variant has a 50% chance of passing the condition on to their offspring. Once such a variant is detected in an individual, it is possible to identify at-risk relatives who can pursue testing for this specific familial variant. Many cases are inherited from a parent, but some cases can occur spontaneously (i.e., an individual with a pathogenic variant has parents who do not have it).
Additionally, individuals with a pathogenic variant in BRIP1 are carriers of Fanconi anemia type J. Fanconi anemia is an autosomal recessive disorder that is characterized by bone marrow failure and variable presentation of anomalies, including short stature, abnormal skin pigmentation, abnormal thumbs, malformations of the skeletal and central nervous systems, and developmental delay (PMID: 8986277, 20417588). Risks for leukemia and early onset solid tumors are significantly elevated (PMID: 12393424, 12393516, 20507306). For there to be a risk of Fanconi anemia in offspring, both parents would each have to have a single pathogenic variant in BRIP1; in such a case, the risk of having an affected child is 25%.
The National Comprehensive Cancer Network® (NCCN) recommends consideration of prophylactic salpingo-oophorectomy (surgical removal of the ovaries and fallopian tubes) for women with a pathogenic variant in BRIP1 after childbearing is complete. The current evidence is insufficient to make a firm recommendation as to the optimal age for this procedure. However, based on the current, limited evidence base, a discussion about surgery should be held around 45-50 years of age or earlier based on a specific family history of early-onset ovarian cancer ( National Comprehensive Cancer Network®. Genetic/Familial High-Risk Assessment: Breast and Ovarian. Version 1.2017). Women electing to defer prophylactic oophorectomy can consider screening with” or “using serum CA-125 and transvaginal ultrasound; however, data do not support such screening and it should not be a substitute for preventive surgery. The current NCCN guidelines do not recommend additional breast cancer screening for individuals with a single pathogenic BRIP1 variant beyond what is recommended for the general population. However, they caution that cancer screening should ultimately be guided by personal and family history ( National Comprehensive Cancer Network®. Genetic/Familial High-Risk Assessment: Breast and Ovarian. Version 1.2017).
An individual’s cancer risk and medical management are not determined by genetic test results alone. Overall cancer risk assessment incorporates additional factors, including personal medical history, family history, and any available genetic information that may result in a personalized plan for cancer prevention and surveillance.
Knowing if a pathogenic variant in BRIP1 is present is advantageous. At-risk relatives can be identified, enabling pursuit of a diagnostic evaluation. Further, the available information regarding hereditary cancer susceptibility genes is constantly evolving and more clinically relevant data regarding BRIP1 are likely to become available in the near future. Awareness of this cancer predisposition encourages patients and their providers to inform at-risk family members, to diligently follow screening protocols, and to be vigilant in maintaining close and regular contact with their local genetics clinic in anticipation of new information.
Review date: October 2016
Invitae is a College of American Pathologists (CAP)-accredited and Clinical Laboratory Improvement Amendments (CLIA)-certified clinical diagnostic laboratory performing full-gene sequencing and deletion/duplication analysis using next-generation sequencing technology (NGS).
Our sequence analysis covers clinically important regions of each gene, including coding exons, +/- 10 base pairs of adjacent intronic sequence in the transcript listed below. In addition, analysis covers the select non-coding variants specifically defined in the table below. Any variants that fall outside these regions are not analyzed. Any specific limitations in the analysis of these genes are also listed in the table below.
Based on validation study results, this assay achieves >99% analytical sensitivity and specificity for single nucleotide variants, insertions and deletions <15bp in length, and exon-level deletions and duplications. Invitae's methods also detect insertions and deletions larger than 15bp but smaller than a full exon but sensitivity for these may be marginally reduced. Invitae’s deletion/duplication analysis determines copy number at a single exon resolution at virtually all targeted exons. However, in rare situations, single-exon copy number events may not be analyzed due to inherent sequence properties or isolated reduction in data quality. Certain types of variants, such as structural rearrangements (e.g. inversions, gene conversion events, translocations, etc.) or variants embedded in sequence with complex architecture (e.g. short tandem repeats or segmental duplications), may not be detected. Additionally, it may not be possible to fully resolve certain details about variants, such as mosaicism, phasing, or mapping ambiguity. Unless explicitly guaranteed, sequence changes in the promoter, non-coding exons, and other non-coding regions are not covered by this assay. Please consult the test definition on our website for details regarding regions or types of variants that are covered or excluded for this test. This report reflects the analysis of an extracted genomic DNA sample. In very rare cases, (circulating hematolymphoid neoplasm, bone marrow transplant, recent blood transfusion) the analyzed DNA may not represent the patient's constitutional genome.
|Gene||Transcript reference||Sequencing analysis||Deletion/Duplication analysis|